Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJohnson Matthey Regulatory News (JMAT)

Share Price Information for Johnson Matthey (JMAT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,551.00
Bid: 1,548.00
Ask: 1,552.00
Change: -28.00 (-1.77%)
Spread: 4.00 (0.258%)
Open: 1,575.00
High: 1,584.00
Low: 1,547.00
Prev. Close: 1,579.00
JMAT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

23 Jul 2014 07:00

RNS Number : 0425N
Johnson Matthey PLC
23 July 2014
 



 

 

 

 

For release at 7.00 am on Wednesday 23rd July 2014

 

 

Johnson Matthey Plc - Q1 Interim Management Statement

 

Progress in First Quarter

 

At today's Annual General Meeting to be held at 11.00 am, Tim Stevenson, Chairman of Johnson Matthey, will make the following statement on the group's trading in its first quarter covering the period from 1st April 2014 to date. Unless otherwise stated, figures quoted in this statement are for the quarter ended 30th June 2014.

 

"Johnson Matthey made progress in the first quarter of 2014/15 in the face of previously described headwinds from the effect of foreign currency translation and from the loss of commission revenue from Anglo American Platinum. Sales excluding precious metals (sales) were flat at £749 million (Q1 2013/14 £745 million) with growth in Emission Control Technologies offset by the expected softening in Process Technologies and Precious Metal Products. The group's underlying operating profit fell by 11% to £103.6 million (Q1 2013/14 £116.1 million). Underlying profit before tax was 10% lower at £95.0 million (Q1 2013/14 £106.0 million).

 

Excluding the impact of foreign exchange movements of approximately £50 million and the loss of around £10 million in commission income from Anglo, the group grew sales by 9%. The effect of exchange on underlying operating profit in the period was £8 million.

 

The group's balance sheet remains strong with net debt of £771 million and net debt (including post tax pension deficits) to EBITDA for the 12 months to 30th June 2014 of 1.4 times.

 

Emission Control Technologies (ECT)

ECT's sales in the quarter were up 10% to £444 million (Q1 2013/14 £404 million) and underlying operating profit was also ahead of last year. Sales of light duty vehicle catalysts increased by 6% to £263 million (Q1 2013/14 £248 million), ahead of the growth in the global car market, benefiting from the slight recovery in Western European car sales and continued growing demand in China. In our heavy duty diesel (HDD) catalyst business, sales grew more strongly and were up 16% at £181 million (Q1 2013/14 £156 million) with growth across all regions. In particular, the business benefited from good demand for trucks in the US, the continued ramp up of Euro IV legislation in China and the recently introduced legislation in Europe (Euro VI). Our HDD sales in Europe were supported by the higher sales value of Euro VI catalysts and also by some continued pipeline filling of our customers' inventory of Euro VI parts which we believe is now largely complete.

 

Process Technologies

As anticipated, Process Technologies had a softer first quarter as a result of the timing of new projects and catalyst orders in its Chemicals businesses. The division's sales were down 17% to £119 million (Q1 2013/14 £144 million) and underlying operating profit was also lower. The Oil and Gas businesses performed well, supported by good demand for refinery catalysts and additives, although this was more than offset by lower catalyst sales and the continued slower pace of licensing activity in the Chemicals businesses. Two new licences, one for a substitute natural gas plant and one for an oleochemicals based process, were secured in the period. With catalyst orders in the Chemicals businesses expected to increase, we currently anticipate that the division's first half performance will be broadly in line with that of the first half of last year and we continue to expect that the division will make progress in 2014/15.

 

Precious Metal Products

The performance of Precious Metal Products in the first quarter was impacted by around £10 million as a result of the change in our Anglo Platinum contracts. Overall, sales in the division fell by 8% to £101 million (Q1 2013/14 £110 million) and underlying operating profit also reduced. In the division's Services businesses, platinum group metal (pgm) refining volumes were steady although our gold and silver refining business saw continued weakness, particularly for refining of secondary material. Sales in the division's Manufacturing businesses were ahead of last year, partly as a result of stronger demand in Europe for Noble Metals' products.

 

Fine Chemicals

Sales in Fine Chemicals were broadly in line at £78 million (Q1 2013/14 £81 million) and operating profit was ahead. The Active Pharmaceutical Ingredient (API) Manufacturing business grew its sales of APIs for ADHD treatments and bulk opiates. However, demand for speciality opiates was down. The Catalysis and Chiral Technologies business continued to make progress but demand in North America in Research Chemicals remained subdued.

 

New Businesses

Sales in New Businesses were steady at £18 million (Q1 2013/14 £20 million). Our Battery Technologies business made progress and expects to complete the previously announced acquisition of certain battery material manufacturing assets from A123 in the second quarter. As planned, operating costs for the division were broadly in line with those in the same period last year.

 

Outlook

Looking ahead, demand for the group's products is robust and we continue to anticipate good underlying performance in the business. Our guidance for the year as a whole remains unchanged, despite the further strengthening of sterling. We currently expect that the group's performance in 2014/15 will be broadly in line with 2013/14 as continued growth across the group will be offset by the adverse impact of both the loss of commission revenue from Anglo Platinum, approximately £30 million compared with 2013/14, and by the effect of foreign currency translation, which could reduce reported underlying operating profit by over £25 million if current rates prevail."

 

Conference Call for Analysts and Investors

Den Jones, Group Finance Director, will host a conference call at 8.00 am today, Wednesday 23rd July 2014, to discuss this Interim Management Statement.

 

The dial-in number for UK callers is 0800 678 1161; for overseas callers the number is +44 1296 311 600; and the passcode is 253556#. Please dial in at least 5 to 10 minutes prior to the start of the conference call to allow time for registration.

 

 

Enquiries:

 

Sally Jones

Director, IR and Corporate Communications

020 7269 8407

Howard Lee

The HeadLand Consultancy

020 7367 5225

www.matthey.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSDMGZNNZKGDZM
Date   Source Headline
14th Jun 20243:00 pmRNSHolding(s) in Company
6th Jun 20249:00 amRNSAnnual Financial Report
28th May 202410:13 amRNSHolding(s) in Company
23rd May 20247:00 amRNSJohnson Matthey Full Year Results
21st May 20245:04 pmRNSHolding(s) in Company
20th May 20245:04 pmRNSHolding(s) in Company
16th May 20244:43 pmRNSDirector/PDMR Shareholding
16th May 20244:11 pmRNSHolding(s) in Company
14th May 202412:05 pmRNSHolding(s) in Company
3rd May 20243:31 pmRNSHolding(s) in Company
2nd May 20249:00 amRNSHolding(s) in Company
22nd Apr 20243:39 pmRNSHolding(s) in Company
18th Apr 20245:33 pmRNSDirector/PDMR Shareholding
17th Apr 20243:07 pmRNSHolding(s) in Company
10th Apr 20243:10 pmRNSHolding(s) in Company
10th Apr 20249:47 amRNSHolding(s) in Company
9th Apr 20249:00 amRNSHolding(s) in Company
8th Apr 20249:00 amRNSHolding(s) in Company
3rd Apr 20245:16 pmRNSHolding(s) in Company
2nd Apr 20249:01 amRNSHolding(s) in Company
2nd Apr 20249:00 amRNSHolding(s) in Company
27th Mar 20241:46 pmRNSHolding(s) in Company
22nd Mar 20243:11 pmRNSHolding(s) in Company
21st Mar 202412:13 pmRNSDirector/PDMR Shareholding
20th Mar 20247:00 amRNSJohnson Matthey sale of Medical Device Components
18th Mar 20243:05 pmRNSHolding(s) in Company
18th Mar 20242:32 pmRNSHolding(s) in Company
12th Mar 20245:12 pmRNSHolding(s) in Company
12th Mar 20249:00 amRNSHolding(s) in Company
11th Mar 20249:00 amRNSHolding(s) in Company
7th Mar 20244:20 pmRNSHolding(s) in Company
22nd Feb 20244:53 pmRNSDirector/PDMR Shareholding
20th Feb 20243:57 pmRNSHolding(s) in Company
19th Feb 20243:12 pmRNSHolding(s) in Company
15th Feb 20249:54 amRNSDirector/PDMR Shareholding
9th Feb 20244:17 pmRNSHolding(s) in Company
9th Feb 202412:31 pmRNSDirector/PDMR Shareholding
8th Feb 20242:17 pmRNSHolding(s) in Company
1st Feb 20244:08 pmRNSHolding(s) in Company
29th Jan 20243:22 pmRNSHolding(s) in Company
29th Jan 20242:37 pmRNSHolding(s) in Company
29th Jan 20242:35 pmRNSHolding(s) in Company
23rd Jan 20244:47 pmRNSHolding(s) in Company
19th Jan 20242:18 pmRNSHolding(s) in Company
18th Jan 20242:30 pmRNSHolding(s) in Company
18th Jan 202411:54 amRNSDirector/PDMR Shareholding
10th Jan 20241:29 pmRNSHolding(s) in Company
9th Jan 20241:31 pmRNSHolding(s) in Company
5th Jan 20244:50 pmRNSHolding(s) in Company
4th Jan 20244:26 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.